<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04946383</url>
  </required_header>
  <id_info>
    <org_study_id>IHB-QD-001</org_study_id>
    <nct_id>NCT04946383</nct_id>
  </id_info>
  <brief_title>Safety and Effectivness of Quercetin &amp; Dasatinib on Epigenetic Aging</brief_title>
  <official_title>The Safety and Effectivness of Quercetin and Dasatinib on the Epigenetic Aging Rates in Healthy Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TruDiagnostic</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TruDiagnostic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessing the effects of Quercitin and Dasatinib over a 16 week period on participatns'&#xD;
      epigenetic biological aging. The patients are being tested at baseline, halfway point, and&#xD;
      after the trial period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective non-randomized clinical study of 20-25 patients to evaluate the&#xD;
      effectiveness of Quercetin and Dasatinib supplements on the patient's epigenetic aging rate.&#xD;
      The investigators predict that Quercetin and Dasatinib combined will slow cell proliferation&#xD;
      and thus decelerate the rate of aging.&#xD;
&#xD;
      There is evidence that Quercetin and Dasatinib slows cell proliferation and decelerates aging&#xD;
      and the risk of age-related diseases. The aim of this pilot study is to evaluate the safety,&#xD;
      efficacy and feasibility of Quercetin and Dasatinib as an effective treatment option to&#xD;
      improve clinical care of healthy individual's epigenetic aging rate thus prolonging&#xD;
      longevity.&#xD;
&#xD;
      Despite considerable effort, successful treatment of reversing one's biological age has been&#xD;
      shown to be a difficult therapeutic challenge. There is evidence that&#xD;
      Dasatinib+Quercetin(Quercetin and Dasatinib) is a safe and effective treatment option to&#xD;
      improve clinical care of healthy individual's biological age. Studies have shown that&#xD;
      Dasatinib+Quercetin slows cell proliferation and decelerates aging and the risk of&#xD;
      age-related diseases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 16, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>prospective non-randomized clinical study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Epigenetic Age Test</measure>
    <time_frame>Change from baseline to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Examining Methylation changes</measure>
    <time_frame>Change from baseline to 6 months</time_frame>
    <description>Methylation analysis via the Illumina 850k epic array. Methylation will be assessed at 850,000 spots on the DNA, these are located on CpG sites. These are the spots on DNA that have cytosine and guanine right next to each other.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Aging</condition>
  <arm_group>
    <arm_group_label>Quercetin and Dasatinib supplements</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500mg Quercetin and 50mg Dasatinib oral capsules on Monday, Tuesday, Wednesday (3 days in a row) per month for the duration of 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib plus Quercetin</intervention_name>
    <description>Dasatinib plus Quercetin</description>
    <arm_group_label>Quercetin and Dasatinib supplements</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women&#xD;
&#xD;
          -  Ages 40 and older&#xD;
&#xD;
          -  Patient must be able to comply with treatment plan and laboratory tests&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Neoplastic cancer within 5 years prior to screening, except for cutaneous basal cell&#xD;
             or squamous cell cancer resolved by excision&#xD;
&#xD;
          -  No immune system issues or immunodeficiency disease&#xD;
&#xD;
          -  No history of viral illness which could be reactivated by immune down regulation&#xD;
&#xD;
          -  Presence of clinically significant acute or unstable cardiovascular and&#xD;
             cerebrovascular (stroke)&#xD;
&#xD;
          -  Diagnosis of a transient ischemic attack in the 6 months prior to screening&#xD;
&#xD;
          -  Patients infected with hepatitis, C or HIV&#xD;
&#xD;
          -  Patients with Body Mass Index (BMI) &gt; 40 kg/m2&#xD;
&#xD;
          -  Presence of active infection 9. Any other illness, psychiatric disorder, alcohol or&#xD;
             chemical dependence that in the opinion of the investigator would render a patient&#xD;
             unsuitable to participate in the study&#xD;
&#xD;
          -  Unable or unwilling to provide required blood sample for testing&#xD;
&#xD;
          -  As for the male-participants they are recommended to avoid fertilization for the first&#xD;
             6 months after the clinical trial.&#xD;
&#xD;
          -  If the patient has previously used Quercetin and Dasatinib.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edwin Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Institute for Hormonal Balance</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Institute for Hormonal Balance</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cavalcante MB, Saccon TD, Nunes ADC, Kirkland JL, Tchkonia T, Schneider A, Masternak MM. Dasatinib plus quercetin prevents uterine age-related dysfunction and fibrosis in mice. Aging (Albany NY). 2020 Jan 18;12(3):2711-2722. doi: 10.18632/aging.102772. Epub 2020 Jan 18.</citation>
    <PMID>31955151</PMID>
  </reference>
  <reference>
    <citation>Hickson LJ, Langhi Prata LGP, Bobart SA, Evans TK, Giorgadze N, Hashmi SK, Herrmann SM, Jensen MD, Jia Q, Jordan KL, Kellogg TA, Khosla S, Koerber DM, Lagnado AB, Lawson DK, LeBrasseur NK, Lerman LO, McDonald KM, McKenzie TJ, Passos JF, Pignolo RJ, Pirtskhalava T, Saadiq IM, Schaefer KK, Textor SC, Victorelli SG, Volkman TL, Xue A, Wentworth MA, Wissler Gerdes EO, Zhu Y, Tchkonia T, Kirkland JL. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019 Sep;47:446-456. doi: 10.1016/j.ebiom.2019.08.069. Epub 2019 Sep 18. Erratum in: EBioMedicine. 2020 Feb;52:102595.</citation>
    <PMID>31542391</PMID>
  </reference>
  <reference>
    <citation>Ermogenous C, Green C, Jackson T, Ferguson M, Lord JM. Treating age-related multimorbidity: the drug discovery challenge. Drug Discov Today. 2020 Aug;25(8):1403-1415. doi: 10.1016/j.drudis.2020.06.016. Epub 2020 Jun 20. Review.</citation>
    <PMID>32574698</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 11, 2021</study_first_submitted>
  <study_first_submitted_qc>June 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2021</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Quercetin</keyword>
  <keyword>Dasatinib</keyword>
  <keyword>Epigenomics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
    <mesh_term>Quercetin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

